Your browser doesn't support javascript.
loading
Robot-assisted nephroureterectomy: surgical and mid-term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group).
Ditonno, Francesco; Franco, Antonio; Wu, Zhenjie; Wang, Linhui; Abdollah, Firas; Simone, Giuseppe; Correa, Andres F; Ferro, Matteo; Perdonà, Sisto; Amparore, Daniele; Bhanvadia, Raj; Brönimann, Stephan; Puri, Dhruv; Mendiola, Dinno F; Ben-David, Reuben; Moon, Sol C; Yong, Courtney; Moghaddam, Farshad S; Ghoreifi, Alireza; Bologna, Eugenio; Licari, Leslie Claire; Finati, Marco; Tuderti, Gabriele; Helstrom, Emma; Tozzi, Marco; Tufano, Antonio; Rais-Bahrami, Soroush; Sundaram, Chandru P; Mehrazin, Reza; Gonzalgo, Mark L; Derweesh, Ithaar H; Porpiglia, Francesco; Singla, Nirmish; Margulis, Vitaly; Antonelli, Alessandro; Djaladat, Hooman; Autorino, Riccardo.
Afiliação
  • Ditonno F; Department of Urology, Rush University, Chicago, IL, USA.
  • Franco A; Department of Urology, University of Verona, Verona, Italy.
  • Wu Z; Department of Urology, Rush University, Chicago, IL, USA.
  • Wang L; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Abdollah F; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Simone G; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
  • Correa AF; Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.
  • Ferro M; Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Perdonà S; Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy.
  • Amparore D; Istituto Nazionale Tumori di Napoli, IRCCS 'Fondazione G. Pascale', Naples, Italy.
  • Bhanvadia R; Division of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
  • Brönimann S; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Puri D; Brady Urological Institute, School of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
  • Mendiola DF; Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.
  • Ben-David R; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Moon SC; Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
  • Yong C; Department of Urology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Moghaddam FS; Department of Urology, Indiana University, Indianapolis, IN, USA.
  • Ghoreifi A; Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
  • Bologna E; Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
  • Licari LC; Department of Urology, Rush University, Chicago, IL, USA.
  • Finati M; Department of Urology, Rush University, Chicago, IL, USA.
  • Tuderti G; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
  • Helstrom E; Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.
  • Tozzi M; Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Tufano A; Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy.
  • Rais-Bahrami S; Istituto Nazionale Tumori di Napoli, IRCCS 'Fondazione G. Pascale', Naples, Italy.
  • Sundaram CP; Department of Urology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Mehrazin R; Department of Urology, Indiana University, Indianapolis, IN, USA.
  • Gonzalgo ML; Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
  • Derweesh IH; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Porpiglia F; Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.
  • Singla N; Division of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
  • Margulis V; Brady Urological Institute, School of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
  • Antonelli A; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Djaladat H; Department of Urology, University of Verona, Verona, Italy.
  • Autorino R; Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.
BJU Int ; 2024 Sep 12.
Article em En | MEDLINE | ID: mdl-39263834
ABSTRACT

OBJECTIVE:

To analyse surgical, functional, and mid-term oncological outcomes of robot-assisted nephroureterectomy (RANU) in a contemporary large multi-institutional setting. PATIENTS AND

METHODS:

Data were retrieved from the ROBotic surgery for Upper tract Urothelial cancer STtudy (ROBUUST) 2.0 database, an international, multicentre registry encompassing data of patients with upper urinary tract urothelial carcinoma undergoing curative surgery between 2015 and 2022. The analysis included all consecutive patients undergoing RANU except those with missing data in predictors. Detailed surgical, pathological, and postoperative functional data were recorded and analysed. Oncological time-to-event outcomes were recurrence-free survival (RFS), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS). Survival analysis was performed using the Kaplan-Meier method, with a 3-year cut-off. A multivariable Cox proportional hazard model was built to evaluate predictors of each oncological outcome.

RESULTS:

A total of 1118 patients underwent RANU during the study period. The postoperative complications rate was 14.1%; the positive surgical margin rate was 4.7%. A postoperative median (interquartile range) estimated glomerular filtration rate decrease of -13.1 (-27.5 to 0) mL/min/1.73 m2 from baseline was observed. The 3-year RFS was 59% and the 3-year MFS was 76%, with a 3-year OS and CSS of 76% and 88%, respectively. Significant predictors of worse oncological outcomes were bladder-cuff excision, high-grade tumour, pathological T stage ≥3, and nodal involvement.

CONCLUSIONS:

The present study contributes to the growing body of evidence supporting the increasing adoption of RANU. The procedure consistently offers low surgical morbidity and can provide favourable mid-term oncological outcomes, mirroring those of open NU, even in non-organ-confined disease.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article